Skip to Content

ProtoKinetix Targets Diabetes and Other Diseases Caused by Inflammation

VANCOUVER, British Columbia--(BUSINESS WIRE)--Feb 23, 2011 - ProtoKinetix (OTCBB: PKTX) ( ), a biotechnology company that has developed and patented a family of synthetic anti-aging glycopeptides (AAGP™) for medicine, biotechnology and cosmetic industries stated that it has repeatedly demonstrated the ability of their AAGP™ molecule to protect against the attacks of the most hostile inflammation causing agents known. Chronic and acute inflammation is the cause of countless diseases and premature death. As a result, containment, control or prevention of inflammation is, without question, one of the most important, universal health care objectives.

In the short term, ProtoKinetix is undertaking a series of independent tests towards the development of a disease specific therapeutic program. ProtoKinetix is embarking on the structuring of a partnership / licensing agreement to develop treatments for autoimmune diseases and chronic conditions. As an example, the inflammation of the pancreatic cells that produce insulin is now recognized as the cause of Diabetes.

This new direction of focus for ProtoKinetix has been made possible by the successful economic scale up of production of AAGP™ and the evaluation of the extensive testing done to date. The Company will now be in a position to better satisfy the testing demands throughout the world.

To date, medicine had limited options available in the treatment and containment of chronic inflammation. ProtoKinetix strongly believes that the AAGP™ family of molecules will prove to be a powerful therapeutic agent against all inflammatory diseases.

About ProtoKinetix

ProtoKinetix, Inc. is a biotechnology company that has developed and patented a family of synthetic anti-aging glycopeptides (AAGP™) for medicine and the biotechnology and cosmetic industries. PKTX's primary focus is on the therapeutic potential for AAGP™ in the treatment of Diabetes, inflammatory diseases, skin protection and anti-aging.

The Private Securities Litigation Reform Act of 1995 provides a “safe harbor” for forward-looking statements. Some information included in this press release contains statements that are forward-looking. Such forward-looking information involves significant risks and uncertainties that could affect anticipated results in the future and, accordingly, these results may differ materially from those expressed in any forward-looking statements made by or on behalf of the Company. For a description of additional risks and uncertainties, please refer to the Company's filings with the Securities and Exchange Commission.

Ross L. Senior – President and CEO


Contact: ProtoKinetix Inc.
Blair Henderson



Posted: February 2011